A Phase IIa, Placebo-controlled, Double Blind, Randomised Multicentre Pilot Study to Investigate the Efficacy, Safety and Tolerability of the Monoclonal Antibody ATH3G10 in Patients With ST-elevation Myocardial Infarction

Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major anterior wall infarction or where coronary blood flow is less than normal in spite of successful percutaneous coronary intervention (PCI) have a poor prognosis. There are today no medical treatments that specifically reduce risk in these patients. The acute inflammatory reaction in conjunction with a STEMI and reperfusion by PCI determines the final size of the infarction and the signals leading to left ventricular remodelling.
This study is designed to assess the efficacy and safety of single intravenous injection with ATH3G10, a fully human IgG1 antibody against phosphorylcholine, in high-risk subjects with STEMI. ATH3G10 aims to reduce inflammation and thereby infarction size and remodeling.

开始日期2019-03-29

申办/合作机构

Athera Biotechnologies AB

NL-OMON44302 / Completed临床2期

Double-blinded, randomised, placebo-controlled, multicentre , Phase IIa study to investigate the effect, safety and tolerability of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together with safety and tolerability, in subjects with elevated lipoprotein a (Lp[a ]) - ATH-3G10-005

开始日期2017-12-21

申办/合作机构

Athera Biotechnologies AB

NCT03320265 / Terminated临床2期

Double-blind, Randomised, Placebo-controlled, Multicentre, Phase IIa Study to Investigate the Effect of PC-mAb on Arterial Inflammation in Subjects With Elevated Lipoprotein a

Inflammation and abnormal amount of lipids in the blood are key factors for the development and progression of atherosclerosis (thickening of the artery wall) and cardiovascular disease. Lipoprotein (a) is a pro-inflammatory plasma lipoprotein that is believed to be a risk factor for cardiovascular diseases. Vascular inflammation generates a range of effects, including endothelial dysfunction and migration of white blood cells into the vessel wall, which results in increased risk of cardiovascular events.
This study is designed to assess the effects of multiple monthly intravenous infusions with the fully human antibody called PC-mAb, in subjects with elevated lipoprotein (a).

开始日期2017-10-11

申办/合作机构

Athera Biotechnologies AB

100 项与 Athera Biotechnologies AB 相关的临床结果

登录后查看更多信息

0 项与 Athera Biotechnologies AB 相关的专利（医药）

登录后查看更多信息

项与 Athera Biotechnologies AB 相关的文献（医药）

2020-12-01·JACC. Basic to translational science2区 · 医学

Phosphorylcholine Antibodies Preserve Cardiac Function and Reduce Infarct Size by Attenuating the Post-Ischemic Inflammatory Response

2区 · 医学

ArticleOA

作者: Jukema, J Wouter ; de Vries, Margreet R ; Pluijmert, Niek J ; de Jong, Rob C M ; Quax, Paul H A ; Pettersson, Knut ; Atsma, Douwe E

Phosphorylcholine monoclonal immunoglobulin G antibody attenuates the immediate post-ischemic inflammatory response by reducing the proinflammatory chemokine (C-C motif) ligand 2 chemokine and circulating Ly-6C^hi monocytes. This subsequently enhances the post-ischemic repair process, resulting in limited adverse cardiac remodeling and preservation of cardiac function. Therefore, phosphorylcholine monoclonal immunoglobulin G antibody therapy may be a valid therapeutic approach against myocardial ischemia-reperfusion injury.

2020-04-01·JACC. Basic to translational science2区 · 医学

Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

2区 · 医学

ArticleOA

作者: Abrahamsson, Tommy ; Savisto, Nina ; Saraste, Antti ; Pettersson, Knut ; Wickman, Anna ; Stroes, Erik S G ; Hellberg, Sanna ; Kroon, Jeffrey ; Silvola, Johanna M U ; de Vries, Margreet ; Rinne, Petteri ; Ståhle, Mia ; Roivainen, Anne ; de Jong, Alwin ; Quax, Paul H A ; Saukko, Pekka ; Liljenbäck, Heidi ; Ylä-Herttuala, Seppo ; Knuuti, Juhani

This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of ¹⁸F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.

2011-01-01·Arteriosclerosis, thrombosis, and vascular biology1区 · 医学

Annexin A5 Therapy Attenuates Vascular Inflammation and Remodeling and Improves Endothelial Function in Mice

1区 · 医学

Article

作者: Jukema, J. Wouter ; Ewing, Mark M. ; de Vries, Margreet R. ; Nordzell, Mariette ; Quax, Paul H.A. ; Frostegård, Johan ; Pettersson, Knut ; van Zonneveld, Anton Jan ; de Boer, Hetty C.

Objective—:

Annexin A5 (AnxA5) has antithrombotic, antiapoptotic, and antiinflammatory properties; we investigated its effectiveness against vascular inflammation, remodeling, and dysfunction in accelerated atherosclerosis.

Methods and Results—:

AnxA5 (1 mg/kg per day or vehicle) was investigated in vascular injury models in hypercholesterolemic apolipoprotein E (ApoE)3*Leiden mice. AnxA5 treatment reduced adhesion and infiltration of leukocytes by 71% to 69% ( P =0.015, P =0.031) and macrophages by 51% to 87% ( P =0.014, P =0.018), as well as monocyte chemotactic protein-1 and tumor necrosis factor-α expression in a femoral artery inflammation model (perivascular cuff for 3 days), indicating reduced vascular inflammation. In a vein graft model, 28 days of AnxA5 treatment reduced vein graft thickening (48%; P =0.006) and leukocyte infiltration (46%; P =0.003). In these mice, reduced plasma concentrations of IFN-γ (−72%; P =0.040), granulocyte colony–stimulating factor (−41%; P =0.010), and macrophage inflammatory protein-1β (MIP-1β) (−66%; P =0.020) were measured, indicating reduced systemic inflammation. An in vitro endothelial cell model shows the importance of AnxA5's anticoagulant properties in reducing vascular inflammation. Endothelium-mediated dilatation in hypercholesterolemic ApoE (−/−) mice was improved by 3 days of AnxA5 treatment, shown by improved systolic and diastolic blood pressure reductions in response to metacholine, which could be abolished by l -Nitro-Arginine-Methyl Ester ( l -NAME), indicating nitric oxide involvement.

Conclusion—:

AnxA5 reduced local vascular and systemic inflammation and vascular remodeling and improved vascular function, indicating that it has a therapeutic potential against atherosclerotic cardiovascular diseases.

项与 Athera Biotechnologies AB 相关的新闻（医药）

2021-05-27

·BioSpace

Betagenon AB announces new CEO and new Chairman of the Board

STOCKHOLM, May 27, 2021 /PRNewswire/ -- Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, today announced that James Hall BM, BCh, D.Phil has joined this month as CEO. Dr. Hall brings extensive senior healthcare and life science experience, including 12 years with AstraZeneca. While there, he held a number of commercial, R&D and Business Development roles, including VP Global Marketing for the CV/GI Therapy Area, Global Product VP for Crestor and VP Evaluation for the CV/Metabolism/Renal Therapy Area. Prior to this he was a member of the Pharmaceutical/Medical Products practice at McKinsey & Co. He has a BM, BCh in Clinical Medicine and a D.Phil in Cell Physiology from Oxford University where he was a Rhodes Scholar. Prof. Thomas Edlund, Ph.D., founder of Betagenon, will lead the ongoing scientific interrogation of the target as the Chief Scientific Officer, and joins the Board of Betagenon this month. "I am incredibly excited to join Betagenon as we build on the scientific leadership of Thomas and the team, and drive to clinical proof of concept and show what direct activation of AMPK can deliver to patients," said James. "Having known James professionally for a number of years, I am delighted that he has agreed to take the company and program forward in this next stage of development," said Thomas. Betagenon also announced that Dr. Gunnar Olsson, MD, Ph.D, has been elected as Chairman of the Board at the recent AGM. Dr. Olsson brings more than 30 years' experience in drug development, including 25 years at AstraZeneca. While at AstraZeneca Dr. Olsson held a number of senior roles in Global R&D including Senior VP and leader of the CV & GI Therapy Area. He certified in Cardiology and Internal Medicine in hospitals associated to Karolinska Institutet, where he was adjunct professor for 12 years. In recent years Dr Olsson has worked with innovative biotech companies in the Scandinavian region as board member or advisor. He is currently Chairman of the Board of IRLAB AB and Athera Biotechnologies AB and is a member of the Board of Gesynta AB. Dr. Olsson succeeds Andreas Nordberg as Chairman. Mr. Nordberg will continue as a member of the Board. Betagenon is a clinical stage company that develops its proprietary first in class AMPK activators as therapies for diseases and conditions associated with the global epidemic in metabolic disorders and an aging population. For more information, contact: James Hall, CEO Betagenon AB james.hall@betagenon.com This information was brought to you by Cision The following files are available for download: View original content: SOURCE Betagenon AB

First in Class

100 项与 Athera Biotechnologies AB 相关的药物交易

登录后查看更多信息

100 项与 Athera Biotechnologies AB 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

A-101(Anthera pharma) ( PLA2 )	心血管疾病更多	终止
Phosphorylcholine monoclonal antibody (Athera Biotechnologies) ( PC )	心肌梗塞更多	无进展
Dianexin (Athera Biotechnologies)	急性冠状动脉综合征更多	无进展